Chief Operating Officer

Scott Kraus has experience in executive management roles and has been a key driver in building shareholder value with large and small start-up medical device companies. Most recently, Scott served as VP of Sales & Marketing for CardioFlow, and was responsible for overseeing all commercial functions. Previously, Scott was the Zone General Manager with Abiomed, where he was responsible for driving the adoption of the Impella® percutaneous LVAD system, which was acquired by Johnson & Johnson for $16.6 billion.

Prior to this, he worked for a series of start-ups: Cardiovascular Systems, Inc. (CSI, acquired by Abbott), Intact Vascular (acquired by Philips), and Intersect ENT (acquired by Medtronic), where he gained strategic and tactical experience launching and driving product launches of disruptive technologies in newly created markets, ranging from orbital atherectomy systems and drug-eluting stents to implantable cardiac rhythm management devices.

Most notably, Scott joined CSI as a Product Manager in Germany, where he worked with key opinion leaders to gain knowledge and preparation for designing and developing the go-to-market strategy in the United States. He subsequently served as VP of Sales at CSI (acquired by Abbott for $780 million), where he helped build and lead a 100-person commercial organization that generated $80 million in annual revenue. Scott was instrumental in driving strategic and tactical plans for commercial execution that resulted in achieving market leadership. At Intact Vascular, he held the role of VP of Sales and Market Development, where he worked closely with the CEO to raise the Series A venture funding, which was utilized to fund the OUS post-market TOBA study in Europe, paving the path for the U.S. regulatory strategy.

Scott has worked for a combination of commercial and clinical-stage companies over the course of his 30-year career, and his scope of influence spans sales, marketing, market development, and customer service, including close collaboration with clinical and regulatory teams.

Earlier in Scott’s career he worked at Boston Scientific, C.R. Bard, and Guidant in the coronary, peripheral, and vascular surgery markets, gaining experience in creating new markets and driving the adoption of new technologies and procedures. Scott holds a B.S. in Finance from Villanova University and an M.B.A. from Saint Joseph’s University.